1. Clinical & Scientific Overview
Pregabalin (TIP-MED-000110, Reference Code [7.8]) is classified under
Pain, Inflammation, Rheumatology & Gout Medicines (Ch 07) as a Gabapentinoid; Presynaptic Voltage-Gated Calcium Channel Alpha-2-Delta (α2δ) Subunit Ligand (Neuropathic Pain Modulator & Anticonvulsant).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 07 [7.8], p. 82): Lyrica (Pfizer), Pregabid / Pregabid-NT (Intas), Pregalin / Pregalin-M (Torrent), Maxgalin (Sun Pharma), Neugaba (Sun); Common Indian FDCs: With Methylcobalamin (-M), With Nortriptyline (-NT) — Strengths & Dosage Forms: Oral Capsules / Tablets: 25 mg, 50 mg, 75 mg, 150 mg, 300 mg; Sustained-Release (SR/ER) Tablets: 75 mg SR, 150 mg SR
Oral Capsules / Tablets: 25 mg, 50 mg, 75 mg, 150 mg, 300 mg; Sustained-Release (SR/ER) Tablets: 75 mg SR, 150 mg SR
3. Mechanism of Action & Pharmacodynamics
Gabapentinoid; Presynaptic Voltage-Gated Calcium Channel Alpha-2-Delta (α2δ) Subunit Ligand (Neuropathic Pain Modulator & Anticonvulsant) acting on target receptor/enzyme pathways in Pain, Inflammation, Rheumatology & Gout Medicines (Ch 07): clinical efficacy is mediated via Gabapentinoid; Presynaptic Voltage-Gated Calcium Channel Alpha-2-Delta (α2δ) Subunit Ligand (Neuropathic Pain Modulator & Anticonvulsant) for Diabetic peripheral neuropathic pain (DPNP); post-herpetic neuralgia (PHN); spinal cord injury neuropathic pain and lumbar radiculopathy/sciatica; fibromyalgia; adjunctive therapy for focal (partial) seizures..
4. Therapeutic Indications & Evidence-Supported Uses
- Diabetic peripheral neuropathic pain (DPNP)
- post-herpetic neuralgia (PHN)
- spinal cord injury neuropathic pain and lumbar radiculopathy/sciatica
- fibromyalgia
- adjunctive therapy for focal (partial) seizures
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: General Adult Reference: Neuropathic Pain: Initiate LOW at 25 mg to 50 mg (or 75 mg) once daily at bedtime for 3–7 days to allow CNS tolerance, then titrate if needed to 75 mg twice daily (150 mg/day; max 300 mg/day in DPNP). Dosing strictly depends on renal CrCl! Follow physician prescription.
Administration & Meal Timing: With or without food (oral bioavailability is ≥90% and linear regardless of food; SR tablets are taken after dinner). | At bedtime (10:00 PM) for once-daily initiation or SR regimens; morning and bedtime if twice daily.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: STRICTLY RENAL-FUNCTION DEPENDENT (Excreted >95% unchanged in urine; zero hepatic metabolism)! • CrCl ≥60 mL/min: Start 50–75 mg OD/BD (max 300–600 mg/day). • CrCl 30–59 mL/min: Start 25 mg–50 mg OD/BD (Max 150 mg/day). • CrCl 15–29 mL/min: Start 25 mg once daily at bedtime (Max 75 mg/day). • CrCl <15 mL/min: 25 mg once daily (with supplemental post-haemodialysis dose). Hepatic: No hepatic metabolism; safe in liver disease.
Renal: STRICTLY RENAL-FUNCTION DEPENDENT (Excreted >95% unchanged in urine; zero hepatic metabolism)! • CrCl ≥60 mL/min: Start 50–75 mg OD/BD (max 300–600 mg/day). • CrCl 30–59 mL/min: Start 25 mg–50 mg OD/BD (Max 150 mg/day). • CrCl 15–29 mL/min: Start 25 mg once daily at bedtime (Max 75 mg/day). • CrCl <15 mL/min: 25 mg once daily (with supplemental post-haemodialysis dose). Hepatic: No hepatic metabolism; safe in liver disease.
Renal: STRICTLY RENAL-FUNCTION DEPENDENT (Excreted >95% unchanged in urine; zero hepatic metabolism)! • CrCl ≥60 mL/min: Start 50–75 mg OD/BD (max 300–600 mg/day). • CrCl 30–59 mL/min: Start 25 mg–50 mg OD/BD (Max 150 mg/day). • CrCl 15–29 mL/min: Start 25 mg once daily at bedtime (Max 75 mg/day). • CrCl <15 mL/min: 25 mg once daily (with supplemental post-haemodialysis dose). Hepatic: No hepatic metabolism; safe in liver disease.
7. Contraindications, Precautions & High-Risk Warnings
- Respiratory Depression Warning: Serious, life-threatening respiratory depression can occur when pregabalin is combined with opioids (tramadol), benzodiazepines, or in elderly patients with COPD/severe renal impairment. Caution in Congestive Heart Failure (causes peripheral oedema and weight gain).
Key Clinical Precautions: Renal: STRICTLY RENAL-FUNCTION DEPENDENT (Excreted >95% unchanged in urine; zero hepatic metabolism)! • CrCl ≥60 mL/min: Start 50–75 mg OD/BD (max 300–600 mg/day). • CrCl 30–59 mL/min: Start 25 mg–50 mg OD/BD (Max 150 mg/day). • CrCl 15–29 mL/min: Start 25 mg once daily at bedtime (Max 75 mg/day). • CrCl <15 mL/min: 25 mg once daily (with supplemental post-haemodialysis dose). Hepatic: No hepatic metabolism; safe in liver disease.
8. Adverse Effects Profile
- Somnolence/drowsiness (20–30%), dizziness/ataxia (unsteady gait), peripheral pedal oedema (6–16%), weight gain, blurred vision/diplopia, dry mouth, mild euphoria or confusion.
- Severe balance impairment and hip-fracture falls in the elderly, respiratory depression (with opioids/COPD), worsening congestive heart failure (especially if combined with pioglitazone), angioedema, suicidal ideation (class anticonvulsant warning), myoclonus (in renal accumulation).
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Opioids (tramadol, morphine), Benzodiazepines (clonazepam, alprazolam), Zolpidem, Amitriptyline/Nortriptyline, and Alcohol cause profound additive CNS depression, ataxia, falls, and respiratory depression
- Pioglitazone (TZDs) causes synergistic fluid retention and pedal oedema
- (No hepatic CYP450 interactions)
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Explain that pregabalin calms overactive pain nerves gradually over 1–3 weeks—it is not an instant painkiller like paracetamol. Because standard 75 mg capsules frequently cause severe morning grogginess and unsteadiness in Indian patients, doctors often start with 25 mg or 50 mg at bedtime. Warn about ankle swelling and advise rising carefully at night to use the washroom.
- Meal & Clock Timing Instruction: With or without food (oral bioavailability is ≥90% and linear regardless of food; SR tablets are taken after dinner). (At bedtime (10:00 PM) for once-daily initiation or SR regimens; morning and bedtime if twice daily.)
- Missed Dose Protocol: If once-daily bedtime dose is missed, do not take it the next morning if driving or going out (causes daytime sedation); resume the next bedtime. Never double.
- Geriatric Dispensing Pearl: Critical CGHS Dispensing Alert: In elderly diabetic patients (who often have Stage 3–4 diabetic nephropathy with eGFR 25–45 mL/min), starting a standard Pregabid-NT or Pregalin 75 mg BD causes rapid renal accumulation—presenting within 3–5 days with severe confusion, slurred speech, myoclonic jerks, and falls! Always verify CrCl and recommend starting at 25 mg–50 mg HS plain pregabalin (avoiding '-NT' nortriptyline FDCs in the elderly due to anticholinergic toxicity).
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Oral Capsules / Tablets: 25 mg, 50 mg, 75 mg, 150 mg, 300 mg; Sustained-Release (SR/ER) Tablets: 75 mg SR, 150 mg SR
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 07 [7.8] (p. 82)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [7.10] Allopurinol — Xanthine Oxidase Inhibitor (Purine Analogue; Metabolised to Activ
- [7.11] Febuxostat — Non-Purine Selective Xanthine Oxidase Inhibitor; Urate-Lowering A
- [7.12] Methotrexate (Low-Dose Weekly Immunomodulator / DMARD Regimen) — Folate Antimetabolite (Dihydrofolate Reductase & AICAR Transformy
- [7.13] Thiocolchicoside, Tolperisone Hydrochloride & Chlorzoxazone (Spinal & Central Muscle Relaxants) — Centrally Acting Skeletal Muscle Relaxants & Antispasticity Agent
